These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000166-13 A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. not-yet-due
Ongoing 2004-000168-28 A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer not-yet-due
Completed, but no date 2005-001484-64 Chemotherapy for Radically Resected Loco-regional Relapse A randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer Chemotherapy vs. Observatio... bad-data
Listed as ongoing, but also has a completion date 2005-001893-28 A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer 2013-10-31 bad-data
Not reported 2005-002626-59 A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy 2006-12-31 due-trials
Listed as ongoing, but also has a completion date 2005-003434-18 Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin PLD, Caelyx, Doxil for Women age 66 years or older with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable f... 2011-12-31 bad-data
Ongoing 2005-005666-36 Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer not-yet-due
Ongoing 2006-002600-33 Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer not-yet-due
Listed as ongoing, but also has a completion date 2007-001370-88 A PHASE III TRIAL EVALUATING THE ROLE OF CONTINOUS LETROZOLE VERSUS INTERMITTENT LETROZOLE FOLLOWING 4 TO 6 YEARS OF PRIOR ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE-RECEPTOR POS... 2012-10-08 bad-data
Listed as ongoing, but also has a completion date 2011-004481-15 An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations 2018-10-31 bad-data
Listed as ongoing, but also has a completion date 2012-001896-35 A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by Ve... 2015-12-31 bad-data
Ongoing 2012-003058-10 A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer not-yet-due
Ongoing 2012-005326-29 A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine resp... not-yet-due
Listed as ongoing, but also has a completion date 2013-004770-10 A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers 2018-01-31 bad-data
Ongoing 2014-005387-15 A Phase II Study of Palbociclib plus Fulvestrant versus Placebo plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer not-yet-due
Ongoing 2016-002200-39 A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel as first or second-line treatment in patients with ER-positive/HER2-neg... not-yet-due